West Pharma (WST) Tops Q1 EPS by 18c; Bumps Guidance Higher

West Pharma (NYSE: WST) reported Q1 EPS of $2.30, $0.18 better than the analyst estimate of $2.12. Revenue for the quarter came in at $720 million versus the consensus estimate of $720.92 million.

GUIDANCE:

West Pharma sees FY2022 EPS of $9.30-$9.45, versus the prior range of $9.20-$9.35 and the consensus of $9.28.

For earnings history and earnings-related data on West Pharma (WST) click here.

You May Also Be Interested In

• BofA raises AMD target to $720, sees server CPU TAM tripling to $211B by 2030
• Moody’s upgrades Brinker to Ba1 on Chili’s growth and debt reduction
• General Mills (GIS) Tops Q1 EPS by 3c